Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A P Grigg

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
British Journal of Haematology|December 3, 1999
Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukaemiaA P Grigg, J Szer, J Beresford, et al.
The Medical Journal of Australia|June 5, 1995
Appropriateness of transfusions of red cells, platelets and fresh frozen plasma. An audit in a tertiary care teaching hospitalJ Metz, K M McGrath, M L Copperchini, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 24, 2007
A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioningA P Grigg, J Gibson, P G Bardy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 6, 1999
Phase I and subsequent phase II study of filgrastim (r-met-HuG-CSF) and dose intensified cyclophosphamide plus epirubicin in patients with non-Hodgkin's lymphoma and advanced solid tumorsS M Talbot, D A Westerman, A P Grigg, et al.
Internal Medicine Journal|April 17, 2004
Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infectionsM A Slavin, J Szer, A P Grigg, et al.
British Journal of Haematology|June 1, 1997
Multilineage mobilization of peripheral blood progenitor cells in humans following administration of PEG-rHuMGDFJ E Rasko, R L Basser, J Boyd, et al.
Blood|May 1, 1997
Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancerR L Basser, J E Rasko, K Clarke, et al.
Leukemia|July 31, 2009
The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemiaK D Mason, S L Khaw, K C Rayeroux, et al.
Blood|November 1, 1996
Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activationC J O'Malley, J E Rasko, R L Basser, et al.
Leukemia|September 3, 2010
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCRD M Ross, S Branford, J F Seymour, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
British Journal of Haematology|December 3, 1999
Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukaemiaA P Grigg, J Szer, J Beresford, et al.
The Medical Journal of Australia|June 5, 1995
Appropriateness of transfusions of red cells, platelets and fresh frozen plasma. An audit in a tertiary care teaching hospitalJ Metz, K M McGrath, M L Copperchini, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 24, 2007
A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioningA P Grigg, J Gibson, P G Bardy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 6, 1999
Phase I and subsequent phase II study of filgrastim (r-met-HuG-CSF) and dose intensified cyclophosphamide plus epirubicin in patients with non-Hodgkin's lymphoma and advanced solid tumorsS M Talbot, D A Westerman, A P Grigg, et al.
Internal Medicine Journal|April 17, 2004
Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infectionsM A Slavin, J Szer, A P Grigg, et al.
British Journal of Haematology|June 1, 1997
Multilineage mobilization of peripheral blood progenitor cells in humans following administration of PEG-rHuMGDFJ E Rasko, R L Basser, J Boyd, et al.
Blood|May 1, 1997
Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancerR L Basser, J E Rasko, K Clarke, et al.
Leukemia|July 31, 2009
The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemiaK D Mason, S L Khaw, K C Rayeroux, et al.
Blood|November 1, 1996
Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activationC J O'Malley, J E Rasko, R L Basser, et al.
Leukemia|September 3, 2010
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCRD M Ross, S Branford, J F Seymour, et al.
Pageof 8